Test Price
2,800 AED✅ Home Collection Available
WDR36 Gene Glaucoma (Open Angle Type 1G) Genetic Test in UAE | 2800 AED | DHA Licensed & Approved
Executive Summary & Core Metrics
Diagnostic sensitivity of 99.9% achieved through ISO‑certified NGS processing with 30x mean coverage. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM. Post‑test tele‑counseling by a board‑certified genetics specialist ensures comprehensive result interpretation. Direct insurance verification and appointment scheduling via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) based genetic test analyses the WDR36 gene for mutations associated with primary open‑angle glaucoma type 1G, enabling early detection and personalised risk stratification. The assay is performed on the Illumina® platform with GRCh38 alignment and validated for clinical reporting.
Why Our Test Leads the Market
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity (NGS with 30x mean coverage) | Variable – often limited to Sanger sequencing of selected exons |
| Methodology | Next Generation Sequencing (Illumina® platform, GRCh38 alignment, clinically validated) | Conventional PCR‑based or microarray; may miss novel variants |
| Turnaround & Support | 3–4 Weeks | Included board‑certified genetic consultation & tele‑guidance | Often >5 Weeks, no integrated clinical interpretation |
Physician Insight & Safety Protocols
“Understanding your genetic predisposition to glaucoma is a powerful step toward proactive eye health. This test provides valuable risk information, but it must always be interpreted alongside your complete clinical history and family background. Our team is committed to supporting you with compassionate, evidence‑based guidance every step of the way.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Medication Advisory: Do not discontinue prescribed glaucoma medication or any eye drops without consulting your treating physician. This genetic test is a risk assessment tool and does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not suitable for individuals with known non‑WDR36 genetic syndromes causing glaucoma (e.g., MYOC, CYP1B1) or for acute angle‑closure glaucoma diagnosis.
- Exclusion: The test is not a standalone diagnostic tool; results must be interpreted alongside a comprehensive eye examination.
- Emergency Red Flag: Seek immediate emergency care if you experience sudden severe eye pain, blurred vision, halos around lights, headache, nausea, or vomiting – these may signal an acute glaucoma crisis independent of genetic findings.
Patient FAQ & Clinical Guidance
1. What is the WDR36 gene and its role in glaucoma?
The WDR36 gene regulates cellular processes vital for retinal ganglion cell survival; mutations in this gene increase susceptibility to primary open‑angle glaucoma type 1G.
2. Who should consider this genetic test?
Individuals with a family history of early‑onset open‑angle glaucoma, or those already diagnosed under 50 years of age, should consider this for risk stratification.
3. What does a positive WDR36 mutation result mean?
A positive result indicates an increased lifetime risk for developing glaucoma, not a certainty; it empowers proactive surveillance and earlier intervention if needed.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
This test is conducted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access‑controlled, and processed solely for the purpose of diagnostic reporting and clinical guidance.
Clinical & Logistical Metadata
| Test Name | WDR36 Gene Glaucoma (Open Angle Type 1G) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Saliva |
| Methodology Used | Next Generation Sequencing (NGS) on Illumina® Platform, GRCh38 alignment |
| ICD-10-CM Code | H40.10, Z13.5, Z15.89 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians